Feb 10 2010
SafeStitch Medical, Inc. (OTCBB: SFES) announced today that it has 
      received CE Mark authorization to commercialize its AMID StaplerTM 
      in the European Economic Community. The new stapler is to be used for 
      fixation of mesh in the repair of hernia defects and also for the 
      approximation of tissues, including skin. The AMID Stapler™ is the first 
      surgical stapler designed specifically for use in inguinal hernia 
      repairs using the Lichtenstein method, in which mesh is implanted for 
      reinforcement. SafeStitch announced in November 2009 that it had 
      received 510(k) clearance from the Food and Drug Administration for sale 
      of the AMID StaplerTM in the U.S. market.
    
“The AMID StaplerTM is angled for safety and better 
      visibility and its patented mesh manipulators permit easy and safe mesh 
      placement. Its 17 box–shaped, sharp-tipped titanium staples are designed 
      specifically for this repair”
    
      SafeStitch designed the stapler in collaboration with Dr. Parviz Amid, a 
      pioneer of and renowned expert in the Lichtenstein repair. Dr. Charles 
      J. Filipi, SafeStitch’s Medical Director and former President of the 
      American Hernia Society, noted that “approximately one million hernia 
      repairs are performed in the U.S. each year and the Lichtenstein repair 
      is used in as many as 70% of inguinal hernia repairs worldwide. Based on 
      clinical experience to date, we believe the AMID StaplerTM 
      will make the Lichtenstein repair faster and more attractive to surgeons 
      presently affixing mesh and closing incisions with sutures.”
    
    
      “The AMID StaplerTM is angled for safety and better 
      visibility and its patented mesh manipulators permit easy and safe mesh 
      placement. Its 17 box–shaped, sharp-tipped titanium staples are designed 
      specifically for this repair,” explained Dr. Stewart Davis, SafeStitch’s 
      COO.
    
    
      Jeffrey Spragens, SafeStitch’s President and CEO, noted that, “this CE 
      Mark and FDA clearance marks the completion of the development phase for 
      SafeStitch’s first four products: the SMART DilatorTM, 
      Standard BiteBlock, Airway BiteBlock and the AMID StaplerTM. 
      We continue our commercialization efforts for these products, starting 
      with the launch of the AMID StaplerTM. Our product 
      development efforts are now fully focused on SafeStitch’s minimally 
      invasive gastroplasty devices for obesity and GERD procedures. We have 
      successfully completed our pre-clinical laboratory studies with these 
      gastroplasty devices, and are preparing IDE applications for FDA 
      clearance to conduct multicenter clinical trials.”